Transdermal selegiline in patients receiving electroconvulsive therapy
Related Experiment Video
Updated: Jun 14, 2026
Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy
Published on: April 11, 2019
Pamela J Horn1, Irving Reti, Geetha Jayaram
1Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD, USA. phorn2@jhmi.edu
Background:
Concurrent use of monoamine oxidase inhibitors (MAOIs) during a course of electroconvulsive therapy (ECT) is controversial.
Objective:
In this report, the authors present outcomes of this concurrent treatment approach.
Method:
The authors present two cases of patients taking the newest MAOI approved for depression, namely, transdermal selegiline, while receiving ECT.
Results:
The authors conclude that there is no evidence of complications or adverse events associated with concurrent use of ECT and low-dose transdermally administered selegiline.
Conclusion:
The authors further conclude that beginning a low dose of transdermal selegiline before finishing a course of ECT is a viable option for relapse prevention in the treatment of depression.
More Related Videos
09:07Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
Published on: August 15, 2017
04:29Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Published on: January 7, 2019
Related Concept Videos
01:30Electroconvulsive Therapy
01:23Antidepressant Drugs: MAOIs and Other Agents